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ABSTRACT: Colloidal aggregation is the dominant mecha-
nism for artifactual inhibition of soluble proteins, and controls
against it are now widely deployed. Conversely, investigating
this mechanism for membrane-bound receptors has proven
difficult. Here we investigate the activity of four well-
characterized aggregators against three G protein-coupled
receptors (GPCRs) recognizing peptide and protein ligands.
Each of the aggregators was active at micromolar concen-
trations against the three GPCRs in cell-based assays. This
activity could be attenuated by either centrifugation of the
inhibitor stock solution or by addition of Tween-80 detergent.
In the absence of agonist, the aggregators acted as inverse
agonists, consistent with a direct receptor interaction.
Meanwhile, several literature GPCR ligands that resemble aggregators themselves formed colloids, by both physical and
enzymological tests. These observations suggest that some GPCRs may be artifactually antagonized by colloidal aggregates, an
effect that merits the attention of investigators in this field.
Since the advent of the molecular era, target-based assayshave been central to both drug discovery and chemical
biology1 and have been especially prominent in high
throughput screening (HTS). A key challenge in these assays
is the occurrence of false-positive hits, which can account for
more than 95% of the active molecules in a screen. Many
mechanisms have been proposed to explain these nuisance hits,
including chemical reactivity,2 assay and reporter-gene
interference,3−6 flexibility,7 oxidation potential,8 formal charge,9
liability to degradation and precipitation,10 and the chemotypes
of “heavy-hitters”.11 The dominant mechanism of artifactual
inhibition, and occasionally of artifactual activation,12 of soluble
proteins, however, is the formation of colloidal aggregates by
the organic molecules being screened.13−17 These colloids have
characteristic features: they are several orders of magnitude
larger than the proteins that they inhibit, ranging from about 50
to over 500 nm in radius;18 they experience a critical
aggregation concentration (CAC) that is reversed by dilution;
they are disrupted by several nonionic detergents; they often
exhibit steep dose−response curves;19 and they may be
precipitated by centrifugation.18,20 Once formed, these
aggregates inhibit proteins nonspecifically by partial denatura-
tion.18,21 No class of organic molecule appears to be free from
aggregation, and the phenomenon has been observed among
small molecule hits, leads, natural products, and drugs,22−26
thereby affecting assays in vitro, in cell culture,26,27and in
simulated gastric and intestinal fluids.25,28
Though cell-based assays are similarly prone to false positives
by “frequent hitters”,29−31 inhibition by colloidal aggregates has
thus far only been demonstrated for soluble proteins. Since
membrane-bound receptors account for over 50% of drug
targets, we wondered whether colloids might affect these
receptors in typical cell-based assays. Until now, we have
struggled to gain traction in these systems, in which our
traditional tools of detergent disruption32 and manipulating
protein concentration33 were hard to deploy. In a recent
docking screen against the G protein-coupled receptor (GPCR)
CXCR4, however, we found that several of the hits were active
as aggregators in enzyme-based counter-screens, and could be
precipitated by centrifugation, consistent with their activity via a
colloidal mechanism.34 These observations suggested routes to
investigate colloid-based inhibition more broadly among
GPCRs.
Here, we ask whether well-described colloidal aggregators,
such as tetra-iodophenolphthalein (TIPT), quercetin, clotrima-
zole, and itraconazole, would inhibit GPCRs, and if so, whether
we could develop simple and definitive experiments to identify
them. We looked to see if these well-studied colloid formers
Received: November 27, 2012
Published: February 25, 2013
Article
pubs.acs.org/jmc
© 2013 American Chemical Society 2406 dx.doi.org/10.1021/jm301749y | J. Med. Chem. 2013, 56, 2406−2414
would inhibit the signaling of the peptidergic GPCRs
vasopressin-2 receptor (V2R), chemokine receptor 4 (CCR4),
and C-X-C receptor 3 (CX3CR1), each measured in live cell
assays. We further asked if these compounds would inhibit only
in the concentration range where they are known to form
colloids, and if inhibition could be attenuated by removing or
disrupting the colloids, providing rapid counter-screens. We
found that these well-known aggregators do antagonize the
three GPCRsthis activity is attributed to their colloidal form,
and does not appear to be a property of the soluble forms of
these organic molecules. Correspondingly, several ligands
reported to be active against GPCRs are shown, by light-
scattering and detergent-sensitive activity in counter-screens, to
form colloids at relevant concentrations. Thus, known colloid
formers are active against multiple GPCRs in a manner directly
related to aggregation, and several new GPCR inhibitors appear
to form colloids. The implications for ligand discovery screens
against GPCRs are considered.
■ RESULTS
To explore the effects of colloidal aggregation on GPCR
activity, we used four molecules well-characterized for colloid
formation at micromolar concentrations: clotrimazole, itraco-
nazole, quercetin, and TIPT (Figure 1).20,22,23,25 We used the
chemokine receptors CCR4 and CX3CR1, and the vasopressin
2 receptor (V2R) as model peptide-activated GPCRs,
measuring activity using the β-arrestin recruitment-mediated
luciferase reporter assay that quantifies receptor activation/
inhibition upon ligand binding.35 As the four organic molecules
bear little physical or topological similarity to known ligands of
these GPCRs, we expected soluble, monomeric forms of the
organic molecules to be relatively inert to these targets. Thus,
broad GPCR activity would, in itself, be an indication of colloid
formation.
Our first question was thus whether these known aggregators
have GPCR activity at concentrations above their known CAC
values.20,25 Quercetin, itraconazole, and TIPT inhibited
CCL22-dependent CCR4 activation with IC50 values of 10.2
μM, 0.5 μM, and 3.5 μM, respectively (Table 1). Similarly, all
four of the compounds inhibited CX3CR1 activity after
stimulation with CX3CL1; IC50 values were 2.0 μM for
clotrimazole, 0.1 μM for itraconazole, 4.5 μM for quercetin, and
2.2 μM for TIPT (Table 1). Last, clotrimazole, itraconazole,
quercetin, and TIPT also inhibited vasopressin-dependent
activity of V2R, with IC50 values of 2.7 μM, 0.8 μM, 7.0 μM,
and 0.4 μM, respectively (Table 1). These IC50 values are
within the range where colloidal inhibition has been observed
for these compounds.22,23,25 This promiscuous inhibition of
various GPCR proteins by molecules unrelated to known target
ligands, at concentrations at which these molecules have been
observed to form colloids, suggests that the four aggregating
compounds may be acting as nonspecific colloidal inhibitors of
the three GPCRs. Meanwhile, in nontransfected controls the
colloids had no measurable nonspecific effects on cell viability
(SI Figure S2).
Figure 1. Aggregating small molecules used in this study.
Table 1. Effects of Clotrimazole, Itraconazole, Quercetin, and TIPT on the β-Arrestin Recruitment Assay for CCR4, CX3CR1,
and V2R
a
GPCR CCR4 CX3CR1 V2R



















Clotrimazole NEb NEb NEb 5.7 ± 0.3 (2.0) 5.0 ± 0.1
(10.8 μM)
5.1 ± 0.7 (7.9) 5.6 ± 0.1 (2.7) 4.8 ± 0.2
(15.1)
NEb








6.1 ± 0.2 (0.8) 4.9 ± 0.1
(11.9)
5.2 ± 0.2 (6.0)








TIPT 5.4 ± 0.3 (3.5) NEb 5.0 ± 0.4 (9.9) 5.7 ± 0.3 (2.2) NEb <4 (>32) 6.4 ± 0.1 (0.4) NEb 4.3 ± 0.3
(45.0)
a. The pIC50 and corresponding IC50 values on direct treatment with aggregators, after centrifugation, and with detergent are shown.
bNo effect on
receptor activity.
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Of course, showing inhibition does not fully demonstrate a
colloidal mechanism. It has been shown that colloids can be
removed from solution by centrifugation.18,20,34 To test
whether the colloidal particles were themselves the inhibitory
species, we centrifuged aqueous mixtures of the colloids, and
treated the cells with the resulting supernatant. If colloids are
indeed the inhibitory species, rather than the soluble monomer,
the supernatant should show less activity than the original
mixture. Alternatively, solutions of well-behaved inhibitors are
unaffected by such centrifugation. Consistent with a colloidal
mechanism, the inhibitory potency of all four inhibitors was
substantially weakened by centrifugation, relative to the
noncentrifuged control (Figure 2). Against CCR4, itraconazole
showed a 36-fold increase of its IC50; changes in inhibitory
activity were also pronounced for quercetin (Table 1). Against
CX3CR1, clotrimazole showed an increase in IC50, from 2.0 to
10.8 μM, while the shift for itraconazole was much more
substantial, increasing from 0.1 to 5.0 μM (Table 1). Similarly,
clotrimazole, itraconazole, and quercetin all showed substantial
IC50 increases against the V2R after centrifugation: from 2.7 to
15.1 μM, 0.8 to 11.9 μM, and 7.0 to 37.8 μM, respectively
(Table 1, Figure 2). These results are consistent with a
colloidal-based mechanism, given that removal of colloidal
particles by centrifugation reduced the inhibition caused by
these molecules.
Although the addition of nonionic detergents can disrupt
colloid formation,18 the use of detergents in cell culture often
has toxic effects, and this had long been a stumbling block in
investigating colloidal effects on cell-based assays. However,
recent work has shown that low concentrations of Tween-80
are both well-tolerated in cell culture and disrupt many
colloids.26 To investigate the ability of Tween-80 to disrupt the
colloids formed by clotrimazole, itraconazole, quercetin, and
TIPT, we measured particle formation in the presence and
absence of this detergent by dynamic light scattering (DLS).
We found that Tween-80 completely disrupts the colloids
formed by these small molecule aggregators (Figure 3).
In live cell-based control experiments, the percentage of
Tween-80 tested had little or no measurable effect on the
growth of the cells, nor on the activity of the receptors. We
note that because the Tween-80 is removed with the rest of the
cell media before measuring β-arrestin signaling, via the
induction of luciferase, there is no detergent effect on luciferin
itself or luciferase activity. Knowing that Tween-80 disperses
Figure 2. Centrifugation treatment. Concentration−response curves are shown for CCR4, CX3CR1, and V2R in the β-arrestin recruitment assay.
Circles represent data points for aggregators without treatment; squares represent data points after centrifugation (±SEM). Calculated pIC50 and
IC50 values are displayed in Table 1.
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colloids but does not affect the assay itself, we repeated the β-
arrestin recruitment assays in the presence of Tween-80. Again,
consistent with a colloidal mechanism, the addition of
detergent substantially diminished the activity of all four
inhibitors against the three receptors, from 3- to 200-fold, when
compared to inhibition in the absence of detergent (Figure 4).
Against CCR4, on addition of Tween-80 the IC50 values of
itraconazole and quercetin increased from 0.5 to 11.4 μM and
from 10.2 to >100 μM, respectively, while TIPT’s shift was
more moderate, increasing from 3.5 to 9.9 μM (Table 1).
Against CX3CR1, all four compounds showed substantial
increases in IC50 values on addition of Tween-80: 2.0 to 7.9 μM
for clotrimazole; 0.1 to 20.8 μM for itraconazole; 4.5 to >32
μM for quercetin; and from 2.2 to >32 μM for TIPT (Table 1).
Similarly, the inhibition of V2R decreased substantially in the
presence of detergent: the IC50 for itraconazole increased from
0.8 to 6.0 μM; TIPT increased from 0.4 to 45.0 μM; and the
IC50 for quercetin doubled, from 7.0 to 15.2 μM (Table 1). The
IC50 values calculated for all four aggregators against the
GPCRs measured here are similar to the IC50 values observed
for the same molecules against soluble enzymes that have
become standard markers for aggregation, such as β-lactamase
and cruzain.22,23,25
We also investigated the inhibition of V2R using a second
assay type, Ca2+ mobilization. Similar IC50 values were observed
as with the β-arrestin recruitment assays for all four aggregators
(SI Table S1, Figure S1). Intriguingly, the dose−response
curves were steep in the Ca2+ mobilization assay, with Hill slope
coefficients as high as 5 (SI Table S1); both observations are
consistent with a colloidal mechanism. We note that, in this
Ca2+ mobilization assay, inhibition was unaffected by
centrifugation or detergent treatment. This likely reflects the
composition of the (proprietary) calcium assay dye kits, which
contain fluorescent dyes as well as masking dyes. Many such
dyes are well-known aggregators,26,36−38 and have been shown
Figure 3. Particle formation by colloid-forming molecules measured
by DLS in the (A) absence of Tween-80 and (B) presence of Tween-
80.
Figure 4. Detergent treatment. Concentration−response curves are shown for CCR4, CX3CR1, and V2R in the β-arrestin recruitment assay. Circles
represent data points for aggregators without treatment; squares represent data points after addition of detergent (±SEM). Calculated pIC50 and
IC50 values are displayed in Table 1.
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to interact with each other and other aggregators in nonadditive
ways,39 substantially altering colloidal characteristics and assay
results. Consistent with this view, the assay kit alone formed
colloid-like particles by DLS of 166 nm in size, and inhibited
two unrelated enzymes, chymotrypsin and malate dehydrogen-
ase (SI Table S2). This suggests that components of the assay
kitlikely the dyes contained in itthemselves form colloidal
aggregates. As the Fluo-4 Direct kit composition is proprietary,
these effects cannot be further disentangled. For the purposes
of this study, the key result is that IC50 values measured with
the four aggregators by calcium mobilization are fully consistent
with those measure by a β-arrestin recruitment assay, with
concentration−response slopes that are commensurate with
aggregation-based inhibition of many other targets.18−20
Of the four well-studied aggregators used in this study, the
flavonoid quercetin is among the most promiscuous, appearing
in hundreds of papers with well over 50 reported targets;40
among these, it has been reported to act against at least 12
different GPCRs, including GLP-1 receptor, 5HT2A serotonin
receptor, α2A adrenergic receptor, and the D2 dopamine
receptor.41−45 Whereas quercetin is a well-behaved kinase
inhibitor at mid-nanomolar concentrations, at micromolar
concentrations its broad promiscuity likely reflects a colloid-
based mechanism.46 Knowing that quercetin acted via a colloid-
based mechanism against CCR4, CX3CR1, and V2R, we
wondered whether related flavonoids that have been reported
to act on GPCRs would themselves form colloids. We therefore
tested four flavonoids reported to be active on GPCRs for
colloid formation. At low to midmicromolar concentrations,
two of these, genistein and luteolin, formed particles by DLS
and inhibited two counter-screening enzymes, β-lactamase and
cruzain, in the same midmicromolar range, as they are observed
to be active against multiple GPCRs41,47−51 (Table 3). Also
consistent with colloid formation, enzyme inhibition was
eliminated by the addition of 0.01% (v/v) Trition X-100 and
0.025% (v/v) Tween-80.
Colloidal inhibition, certainly of soluble proteins, arises from
the sequestration of the protein target itself, in a partly
denatured form, by the colloidal particle.20,21 Since CCR4,
CX3CR1, and V2R are all peptidic GPCRs, we wondered if
their antagonism arose from association of the colloids with the
receptors themselves or with their peptide agonists. To test for
an interaction between colloid and peptide, we used DLS to
measure the size of TIPT colloids alone and mixed with
vasopressin. The colloids formed by TIPT substantially increase
in size when mixed with vasopressin, from 56.1 to 97.3 nm in
radius, suggesting that the peptide monomers are being
sequestered onto the colloidal surfaces (Table 2). We also
measured the inhibition of β-lactamase by TIPT colloids with
and without preincubation with vasopressin; proteinsand
perhaps peptidescan prophylactically coat colloids, prevent-
ing inhibition of a second enzyme. TIPT at 10 μM, above the
CAC where colloids appear, leads to 77% inhibition of β-
lactamase; preincubating the colloidal mixture with vasopressin
almost fully blocks this inhibition (7% inhibition), suggesting
that the peptide binds the colloidal surface and competes with
β-lactamase binding. These observations support the idea that
the colloids can directly associate with the peptide ligands,
which could contribute to inhibition by sequestering and
depleting agonist.
While peptide sequestration can thus contribute to apparent
GPCR antagonism, the colloids may also associate with the
receptors themselves, as they do with soluble enzymes. To
investigate this, we measured the effect of the four aggregators
on basal GPCR signaling, which occurs in the absence of
agonist. Three of the four aggregators, clotrimazole, itracona-
zole, and TIPT, inhibited basal receptor activity, acting as
apparent inverse agonists, with IC50 values of 1.6 ± 3.2, 0.2 ±
2.0, and 1.6 ± 6.3 μM, respectively (Figure 5). These
observations support a mechanism where the colloids directly
associate with the GPCRs themselves, acting as inverse
agonists. This mechanism is sufficient to explain their inhibitory
activity, though peptide-agonist sequestration may also play a
role.
■ DISCUSSION
The point of this study is uncomplicated: colloidal aggregation,
well-appreciated as a major artifact in ligand discovery against
soluble proteins, can also affect GPCRs. This conclusion is
supported by two lines of evidence. First, well-studied colloid-
formers inhibit a peptide- and two protein-activated GPCRs in
a colloid-dependent manner: inhibition only occurs in the
concentration range where these molecules aggregate and, in
well-controlled β-arrestin recruitment assays, inhibition is
disrupted by removing the colloidal particles from solution,
either by centrifugation or by addition of detergent. In a
second, complementary line of investigation, flavonoids
reported as active against other GPCRs are shown to form
colloids directly, by dynamic light scattering (DLS) and by
detergent-dependent inhibition of classic counter-screen
enzymes like β-lactamase. Taken together, these results suggest
that colloid-based activity may contribute to artifactual ligand
discovery against G protein-coupled receptors, which remain
crucial targets for probe and drug discovery.
If the key point of this paper is simple, it nevertheless took
substantial effort to learn how to perturb the assays in such a
way as to demonstrate a colloid-based mechanism. Whereas it is
straightforward to show activity of a colloid in a GPCR assay,
mechanistically attributing this to colloids demanded techni-
ques to disrupt them or remove them from solution. The twin
techniques of Tween-80 addition and of centrifugationwhich
may be accomplished on a benchtop microcentrifugewere
key to enabling this study, and are brought together here for the
first time. Both have the virtue of simplicity, and may be
deployed on a large scale. Other investigators may find them
useful as controls for ligand discovery against GPCRs.
Several caveats merit mentioning. Whereas the mechanism of
colloidal inhibition of soluble proteins is relatively well-
understoodsequestration of the protein by the colloid in a
partly denatured form18,20,21their mechanism of action on
GPCRs is only partly illuminated by this study. The observation
that they act as inverse agonists, in the absence of activating
agonist, supports a direct role on the GPCRs themselves.
However, unless the colloids actually strip the GPCRs from the
membrane, this cannot be by exactly the same mechanism as
Table 2. Colloids Sequester Peptidic Ligandsa
sample radius (nm) % β-lactamase activity
Vasopressin 0.18 ± 0.1 101.7 ± 3.7
TIPT 56.1 ± 3.1 23.0 ± 12.1
TIPT + Vasopressin 97.3 ± 9.4 93.0 ± 2.8
aThe particle radii measured by DLS and the corresponding effects on
β-lactamase activity are listed for vasopressin and TIPT alone and in
combination.
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for sequestration of soluble proteins. Indeed, activity via
membrane perturbation cannot be discounted, though in
control experiments colloids showed no gross effect on cell
morphology or viability. Nor can activity via the agonist itself be
discountedindeed, our results suggest that at least peptide
agonists will be sequestered by the colloids, possibly
contributing to inhibition. In some assay formats, aggregating
compound will behave differently. Even here, in the calcium-
mobilization assay, though the aggregating compounds were
just as effective as in the β-arrestin recruitment assay,
reversibility was harder to see. We suspect this owes to the
presence of dyes in the kit used, but this is hard to deconvolute
owing to the proprietary nature of this kit. More broadly, cell-
based assays that include a large amount of protein, such as are
found in serum-related media, will be less susceptible to
colloidal-aggregation; though the colloids themselves often
persist in these and related media,25,26,52 their activity is often
reduced, if not fully eliminated.27 The assays used in this study,
however, remove the serum-supplemented media and replace it
with serum-free media before treatment with compound and
therefore remain quite sensitive to aggregation-based effects.
Finally, it is uncertain what range of GPCRs will be affected by
colloidal aggregationwe have only observed such inhibition
against peptidergic and protein−ligand GPCRs, though the
activity of promiscuous flavonoids on other families of GPCRs
suggests that their effects might be more broad.
These caveats should not obscure the key observation of this
study: colloidal aggregation can lead to artifactual activity
against GPCRs. Given the prevalence of aggregators in
screening libraries,13−16 the artifactual activity of colloidal
aggregators against GPCRs could not only waste much effort
and time, but may mask the activities of weaker but better
behaved compounds in screening campaigns. More positively,
the detergent and spin-down techniques described here may be
readily deployed on a large scale and can rapidly eliminate most
artifacts acting by this mechanism. Given the importance of
these targets in biology and medicine, this mechanism of action
against GPCRs merits close attention.
■ METHODS
Materials. CCL22 and CX3CL1 were purchased from R&D
Biosystems. Bright-Glo luciferase reagent was obtained from Promega.
Clotrimazole was purchased from MP Biomolecules; itraconazole was
purchased from AK Scientific; Arg-vasopressin, quercetin, and TIPT
were purchased from Sigma. All compounds tested had purity of
≥95%.
Cell Culture. HTLA cells were cultured in DMEM, supplemented
with 10% fetal bovine serum (FBS), 100 units/mL penicillin, 100 mg/
mL streptomycin, 5 mg/L puromycin, and 100 mg/L hygromycin
(HTLA media). This cell line was kindly provided by Gilad Barnea in
the Axel laboratory.
β-Arrestin Recruitment Assay. Recruitment of β-arrestin via
agonist-stimulated receptors (CCR4, CX3CR1, and V2R) was
quantified using the previously described β-arrestin recruitment
assay.53 Briefly, HTLA cells stably expressing a β-arrestin2-TEV
protease fusion protein and a tTA-dependent firefly luciferase reporter
gene were plated in HTLA medium. Using a CaPO4 method reported
Table 3. Colloid Formation by Flavonoidsa
aThe colloid radii measured by DLS and the effects on enzyme activity in the presence and absence of detergent are shown.
Figure 5. Concentration−response curves for CCR4 in the β-arrestin recruitment assay in the absence of the CCR4 agonist, CCL22 (±SEM). The
depression of basal activity by the colloid-formers in the absence of the agonist suggests inverse agonism.
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earlier,54 cells were transfected with 18 μg of the receptor-V2-tTA
construct and incubated overnight at 37 °C, 5% CO2 (day 1). The
following day, cells were plated (20 000 cells/well, 50 μL/well) in
white, clear-bottom, PLK-coated, 384-well plates in DMEM containing
1% dialyzed FBS and antibiotics and incubated overnight at 37 °C, 5%
CO2 (day 2). On day 3, the media was replaced by serum-free DMEM
containing antibiotics, and cells were allowed to recuperate for 2−3 h.
Serial dilutions of the reference and test ligands (0.001 nM to 100 μM,
final concentrations, prepared as 6×) were made in sterile drug buffer
(1× HBSS, 20 mM HEPES, 6% DMSO, pH 7.4). For the
centrifugation treatment, concentrated solutions of the ligands were
spun at 13 000g for 20 min on a benchtop microfuge at room
temperature. For the detergent treatment, Tween-80 was added to
concentrated solutions of the ligands for a final concentration of
0.025% (v/v). Cells were stimulated with 10 μL/well of reference or
test ligand, treated or untreated, and incubated for 20 min. Cells were
stimulated a second time with reference ligand at 1 μM and incubated
overnight at 37 °C, 5% CO2. On day 4, the media was removed from
the wells and 20 μL of 10× Brite-Glo reagent (Promega) was added.
Cells were incubated for 30 min at RT and luminescence was read
using a Trilux plate-reader (1 s/well). Data were normalized to vehicle
(0%) and reference ligands (100%) and regressed using the sigmoidal
dose−response function built into GraphPad Prism 5.0.
Dynamic Light Scattering. To measure the effect of Tween-80
on colloid formation, compounds were diluted from concentrated
stocks in DMSO into filtered 1× HBSS containing 20 mM HEPES,
pH 7.4, with and without 0.025% (v/v) Tween-80. The final DMSO
concentration was 1%, and compound concentrations were as follows:
30 μM TIPT and clotrimazole, 1 μM itraconazole, 100 μM quercetin.
Samples were run in triplicate. Figure 3 shows one representative
histogram for each sample. TIPT, genistein, and luteolin samples were
measured in filtered 50 mM potassium phosphate, pH 7.0. To measure
the effect of vasopressin on the size of TIPT colloids, light scattering
was measured for 10 μM TIPT with and without 1 μM vasopressin; 1
μM vasopressin was measured alone in phosphate buffer as well.
Genistein was measured at 50 μM and luteolin was measured at 75
μM. Samples were run in quadruplicate. All measurements were made
at room temperature using a DynaPro MS/X (Wyatt Technology)
with a 55 mW laser at 826.6 nm. The laser power was 100%, and the
detector angle was 90°.
Enzyme Inhibition Assays. AmpC β-lactamase inhibition was
measured in 50 mM potassium phosphate, pH 7.0, at room
temperature. TIPT (10 μM, final concentration) was diluted from a
10 mM stock in DMSO. β-Lactamase was measured with and without
a five minute preincubation with 1 μM vasopressin. β-Lactamase (1
nM) was added to the samples and the mixture was incubated for 5
min; the reaction was initiated by adding 69 μM CENTA substrate
(Tydock Pharma; Modena, Italy). Genistein and luteolin were diluted
from concentration DMSO stocks to obtain full dose−response curves
against β-lactamase with final concentrations of DMSO of 1% (v/v).
Compound was incubated with 0.2 nM β-lactamase for 5 min, with
and without 0.01% (v/v) Triton X-100, and the reaction was initiated
by adding 46 μM CENTA. The final reaction volumes were 1 mL.
Change in absorbance was monitored at 405 nm for 2.5 min using an
HP 8453 UV−vis spectrophotometer (Agilent, Technologies, Santa
Clara, CA). The assay was performed in quadruplicate in methacrylate
cuvettes. Cruzain inhibition was measured in 0.1 M sodium acetate,
pH 5.5, containing 5 mM DTT. Genistein and luteolin were incubated
with 0.8 nM cruzain (with and without 0.025% (v/v) Tween-80) for 5
min until reactions were initiated by adding the fluorogenic substrate
Z-Phe-Arg-aminomethylcoumarin (Z-FR-AMC). The final reaction
volume was 200 μL. Final concentrations were 0.4 nM cruzain, 2.5 μM
Z-FR-AMC, and 1% DMSO. Enzyme inhibition was measured by
monitoring the increase in fluorescence for 5 min (excitation
wavelength of 355 nm, emission wavelength of 460 nm) in a
microtiter plate spectrofluorimeter (FlexStation, Molecular Devices).
Assays were performed in duplicate in 96-well plates and were
repeated in two separate experiments. Dose−response curves were
plotted, and IC50 values were calculated using GraphPad Prism 4
(GraphPad, San Diego, CA) using a sigmoidal dose−response curve
analysis with variable slope.
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